Mid-cap Health Care company Neogen has moved 0.2% so far today on a volume of 167,381, compared to its average of 1,516,182. In contrast, the S&P 500 index moved -1.0%.
Neogen trades 5.41% away from its average analyst target price of $20.5 per share. The 2 analysts following the stock have set target prices ranging from $19.0 to $22.0, and on average have given Neogen a rating of buy.
If you are considering an investment in NEOG, you'll want to know the following:
-
Neogen's current price is 97.0% above its Graham number of $10.97, which implies that at its current valuation it does not offer a margin of safety
-
Neogen has moved -7.5% over the last year, and the S&P 500 logged a change of 16.7%
-
Based on its trailing earnings per share of -0.02, Neogen has a trailing 12 month Price to Earnings (P/E) ratio of -1080.5 while the S&P 500 average is 15.97
-
NEOG has a forward P/E ratio of -1080.5 based on its forward 12 month price to earnings (EPS) of $-0.02 per share
-
The company has a price to earnings growth (PEG) ratio of -14.84 — a number near or below 1 signifying that Neogen is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 1.49 compared to its sector average of 4.16
-
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide.
-
Based in Lansing, the company has 2,108 full time employees and a market cap of $4.67 Billion.